Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2024 Earnings Call Transcript
Operator: Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals’ Fourth Quarter and Full Year 2024 Corporate Update Conference Call.
Verrica Pharmaceuticals Inc. (VRCA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 8,921,000 | $6,244,700 | 0.08% | |
| 2. | Caligan Partners David Johnson | 7,429,687 | $5,200,781 | 1.31% | |
| 3. | Perceptive Advisors Joseph Edelman | 3,249,669 | $2,274,768 | -55% | 0.06% |
| 4. | Renaissance Technologies Jim Simons | 233,300 | $163,310 | +58% | 0% |
| 5. | Citadel Investment Group Ken Griffin | 20,286 | $14,200 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 280,898 | 832,826 | 2024-11-22 | Filing | ||
| $0.00 | 1,123,595 | 1,823,800 | 2024-11-22 | Filing | ||
| $0.00 | 4,494,382 | 5,976,101 | 2024-11-22 | Filing | ||
| $0.00 | 18,426,966 | 26,278,094 | 2024-11-22 | Filing | ||
| $7.24 | 115,774 | Large Shareholder | 7,099,182 | 2023-12-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.65 | 4,315 | 176,458 | 2025-03-17 | Filing | ||
| $2.46 | 9,530 | 105,773 | 2024-08-27 | Filing | ||
| $2.66 | 26,183 | 115,303 | 2024-08-26 | Filing | ||
| $2.46 | 3,601 | 94,261 | 2024-08-27 | Filing | ||
| $2.66 | 9,888 | 97,862 | 2024-08-26 | Filing |
Institutional Investors' Holdings
News See All
15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers
The U.S. Federal Reserve conducting a 50 basis point interest rate cut was the catalyst that stocks needed to bounce back from a period of stagnation.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2024 Earnings Call Transcript
Operator: Good morning, and welcome to the Verrica Pharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q1 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, good morning, and welcome to the Verrica Pharmaceuticals First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript
Verrica Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-0.53 EPS, expectations were $-0.47. Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call.
Hedge Fund and Insider Trading News: Paul Marshall, Crispin Odey, Point72 Asset Management, Asgard Fixed Income Fund, Brookfield Hedge Solutions Advisors, B Riley Financial Inc (RILY), Verrica Pharmaceuticals Inc. (VRCA), and More
GB News owner Sir Paul Marshall’s hedge fund has made a multi-million pound gain on its bet against NatWest shares following the exit of Dame Alison Rose.
12 Most Promising Micro-Cap Stocks According to Analysts
In this article, we will take a look at the 12 most promising micro-cap stocks according to analysts.
Hedge Fund and Insider Trading News: Andreas Halvorsen, Ken Griffin, Bill Ackman, Michael Burry, Welton Investment Partners, CalAmp Corp. (CAMP), Keurig Dr Pepper Inc (KDP), and More
It’s hard to escape Ken Griffin’s name if you live in Chicago.
5 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman
In this article, we discuss the 5 best pharmaceutical stocks to buy according to billionaire Joseph Edelman.
Billionaire Hedge Funds
